VivoSeq
Oncology

Hypopharyngeal Carcinoma

14

Pipeline Programs↗

4

Active Trials↗

8

Companies Involved↗

Hypopharyngeal Carcinoma is an emerging landscape with 14 programs across 8 companies. The most active players are Coherus Oncology, Inc., Jiangsu Simcere Pharmaceutical Co., Ltd., Imclone. 2 therapies are approved with 5 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

42/100

Pipeline Velocity

6/100

Mech. Concentration

29/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

Coherus Oncology, Inc.

1 program

Phase 2Jiangsu Simcere Pharmaceutical Co., Ltd. logo

Jiangsu Simcere Pharmaceutical Co., Ltd.

1 program

Phase 2I

Imclone

1 program

Phase 2M

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

1 program

Phase 3A

Avyxa

1 program

Phase 3Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

76%

Small molecule

13 of 17 classified programs — the dominant modality here.

24%ALL OTHERSMonoclonal antibody424%

Small molecule leads; the ring shows all 17 classified programs, each share of the total. Modality classified for 100% of 17 pipeline programs.

Analysis

Trial Status

9

clinical trials

Unknown status5 · 56%
Recruiting3 · 33%
Not yet recruiting1 · 11%

Clinical Trials

Trial Activity

9 trials

Neoadjuvant PD-1 Inhibitor Combined With Cetuximab and Platinum in Resectable Locally Advanced Hypopharyngeal Carcinoma
Recruiting·EEye & ENT Hospital of Fudan University·Phase 2·NCT06151743·32 enrolled
Neoadjuvant Chemotherapy Combined With Finotonlimab in the Treatment of Locally Advanced Hypopharyngeal Carcinoma
Recruiting·EEye & ENT Hospital of Fudan University·Phase 2·NCT07248956·116 enrolled
A Prospective Exploratory Clinical Study of Metronomic Capecitabine as Adjuvant Therapy in Locoregionally Advanced Hypopharyngeal Carcinoma
Recruiting·EEye & ENT Hospital of Fudan University·N/A·NCT05940441·74 enrolled
Comparing Neoadjuvant Chemotherapy Combined With PD-1 Inhibitor Versus Neoadjuvant Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Carcinoma
Not yet recruiting·FFudan University·Phase 3·NCT06957938·168 enrolled
New Strategy of Improving Treatment Outcome and Larynx-preservation Rate in Locally Advanced Hypopharyngeal Carcinoma
Unknown status·CChinese Academy of Medical Sciences·Phase 2·NCT03558035·96 enrolled
Induction Chemotherapy and Toripalimab Followed by Radiotherapy in Unresectable Laryngeal/Hypopharyngeal Carcinoma
Unknown status·FFudan University·Phase 2·NCT05420597·61 enrolled
Induction Chemotherapy in Locally Advanced Hypopharyngeal Carcinoma: a Randomised Phase 3 Trial
Unknown status·SSun Yat-sen University·Phase 3·NCT04502641·160 enrolled
Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma
Unknown status·EEye & ENT Hospital of Fudan University·Phase 2·NCT04156698·51 enrolled
Induction Chemotherapy and Toripalimab for Larynx Preservation in Resectable Laryngeal/Hypopharyngeal Carcinoma
Unknown status·FFudan University·Phase 2·NCT04995120·42 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)